Citation Impact
Citing Papers
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
2006 Standout
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
2009 StandoutScience
Promoter Choice Determines Splice Site Selection in Protocadherin α and γ Pre-mRNA Splicing
2002 StandoutNobel
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/ neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients
2004
Activation of Akt-1 (PKB-α) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion
2004
Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer
2004
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
2005
Chromosome 11q13.3 variant modifies renal cell cancer risk in a Chinese population
2011
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
Estrogen receptor mutations and their role in breast cancer progression
2014
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
2004
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer
2004
Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer
2005
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Impact of metastatic estrogen receptor and progesterone receptor status on survival
2005
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Estrogen receptors and human disease
2006 Standout
Requirement for CDK4 kinase function in breast cancer
2006
Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
2009 StandoutNobel
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Novel Polymorphisms of Nuclear Receptor SHP Associated with Functional and Structural Changes
2010
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Chromatin Modifications and Their Function
2007 Standout
Expanding functional diversity of the coactivators
2005
Nuclear receptor coregulators as a new paradigm for therapeutic targeting
2010
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
2006 StandoutNobel
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?
2003
Epigenetic codes of PPARγ in metabolic disease
2011
MICoA, a Novel Metastasis-associated Protein 1 (MTA1) Interacting Protein Coactivator, Regulates Estrogen Receptor-α Transactivation Functions
2003
Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database
2002
Cloning and Characterization of Human Estrogen Receptor β Isoforms
1998
Cyclin D1 and breast cancer
2006
International Union of Pharmacology. LXIV. Estrogen Receptors
2006
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Lysine acetylation and the bromodomain: a new partnership for signaling
2004
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells
2008
Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad Neighbors
2005 Standout
Estrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance
2005
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α
2006
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis
2006
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
p21 in cancer: intricate networks and multiple activities
2009 Standout
Acetylation and deacetylation of non-histone proteins
2005
Senescence and epigenetic dysregulation in cancer
2002
Stress and the brain: from adaptation to disease
2005 Standout
Endocrine-responsive breast cancer and strategies for combating resistance
2002
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression
2012 StandoutNobel
Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer
2004
Novel estrogen receptor coregulators and signaling molecules in human diseases
2004
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
2003
Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
2013
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Emerging Biological Principles of Metastasis
2017 Standout
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
2005
Local force and geometry sensing regulate cell functions
2006 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
2003
Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo
2003
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
2005
Principles for modulation of the nuclear receptor superfamily
2004
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
2010
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
Natural Trans-spliced mRNAs Are Generated from the Human Estrogen Receptor-α (hERα) Gene
2002
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
AKT/PKB Signaling: Navigating the Network
2017 Standout
Prognostic molecular markers in early breast cancer
2004
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter
2003
Biological determinants of endocrine resistance in breast cancer
2009
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
2009
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways
2003
Integrating cell-signalling pathways with NF-κB and IKK function
2006 Standout
Mechanisms of implantation: strategies for successful pregnancy
2012 Standout
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21
2015 StandoutNobel
Estrogen-mediated down-regulation of E-cadherin in breast cancer cells.
2003
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
RNA–protein analysis using a conditional CRISPR nuclease
2013 StandoutNobel
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
2005
Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest
2004
Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis
2004
Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) –Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy
2007
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
2000
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
2004
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
2011
Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor α (ERα), Differentially Affect ERα Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells
2003
Breast Cancer Treatment
2019 Standout
Cell Cycle Progression Stimulated by Tamoxifen-Bound Estrogen Receptor-α and Promoter-Specific Effects in Breast Cancer Cells Deficient in N-CoR and SMRT
2005
Mechanisms of Estrogen Action
2001 Standout
Review of the in Vivo Functions of the p160 Steroid Receptor Coactivator Family
2003
Thyroid Hormone Regulation of Metabolism
2014 Standout
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
2004
Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer
2005
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Nuclear Receptor Coactivators: Master Regulators of Human Health and Disease
2013
The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer
2002
Recruitment of Histone Deacetylase 4 to the N-Terminal Region of Estrogen Receptor α
2005
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Estrogen Receptor Mutations in Human Disease
2004
Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know
2003 Standout
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
2003
DNA recognition by nuclear receptors
2004
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
Identification of Tamoxifen-Induced Coregulator Interaction Surfaces within the Ligand-Binding Domain of Estrogen Receptors
2004
Palaeoproteomic evidence identifies archaic hominins associated with the Châtelperronian at the Grotte du Renne
2016 StandoutNobel
A Novel Estrogen Receptor α-Associated Protein Alters Receptor-Deoxyribonucleic Acid Interactions and Represses Receptor-Mediated Transcription
2004
The Interplay between the Glucocorticoid Receptor and Nuclear Factor-κB or Activator Protein-1: Molecular Mechanisms for Gene Repression
2003
The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
2006
Works of Torsten Hopp being referenced
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer
2003
Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment
2001
Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity
2001
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies
2005
Estrogen Receptor Variants
1998
Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2
2003
Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation
2000
Androgen Receptor Acetylation Governs trans Activation and MEKK1-Induced Apoptosis without Affecting In Vitro Sumoylation and trans-Repression Function
2002
Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates
2004
Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer
2004
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
2000